Welcome to our dedicated page for Viatris Ord Shs news (Ticker: VTRS), a resource for investors and traders seeking the latest updates and insights on Viatris Ord Shs stock.
Viatris Inc. (Nasdaq: VTRS) is a global healthcare company that regularly issues news on its operations, strategy and pipeline across generics, established brands and innovative medicines. This news page aggregates company announcements, press releases and third-party coverage related to VTRS, giving readers a single place to review the latest corporate developments.
Viatris frequently reports on regulatory milestones in its global pipeline. Recent updates include FDA approval of octreotide acetate for injectable suspension as a generic version of Sandostatin LAR Depot, FDA acceptance of a New Drug Application for a low dose estrogen weekly contraceptive patch, FDA clearance of an IND for the MR‑146 gene therapy candidate in neurotrophic keratopathy, and acceptance of a Japanese New Drug Application for pitolisant in obstructive sleep apnea syndrome. The company also announces progress in Japan and the Asia-Pacific region, such as the acquisition of Aculys Pharma and rights to pitolisant and Spydia nasal spray.
Investors can also find financial and corporate news, including quarterly results, updates to financial guidance, capital return actions like dividends and share repurchases, and information on enterprise-wide strategic reviews. Viatris’ participation in major healthcare and investor conferences, such as the J.P. Morgan Healthcare Conference and other sector events, is typically announced through press releases that are reflected in the news flow.
Additional news items may cover business development and collaborations, such as research agreements to develop engineered bacteriophage products for ophthalmic infections, as well as governance updates, board appointments and changes to corporate bylaws. For anyone tracking VTRS, this page offers a concise view of how Viatris communicates its strategy to strengthen its core portfolio, expand innovative brands and optimize its global structure.
Viatris (Nasdaq: VTRS) reported that its Phase 3 study of pimecrolimus 0.3% (MR-139) ophthalmic ointment for blepharitis failed to meet its primary endpoint of complete debris resolution after six weeks of twice-daily treatment.
The company is now evaluating next steps for the Phase 3 program, which may include revising the planned additional Phase 3 study. Despite this setback, Viatris highlighted recent successes with other pipeline products, including positive Phase 3 results from the LYNX-2 trial of MR-142 for keratorefractive conditions and the VEGA-3 Trial of MR-141 for presbyopia.
Viatris (NASDAQ:VTRS) announced positive top-line results from its VEGA-3 Phase 3 trial for MR-141, a treatment for presbyopia. The randomized, placebo-controlled study involving 545 patients met its primary and all secondary endpoints, demonstrating significant improvement in near vision without compromising distance vision.
The trial showed statistically significant results (p<0.0001) in achieving ≥3-line gain in binocular distance-corrected near visual acuity. Patients reported significant functional benefits and satisfaction with near vision improvements, particularly in dim lighting conditions. The safety profile remained consistent with previous trials, with no treatment-related serious adverse events.
Viatris plans to submit an FDA application in H2 2025 for MR-141, targeting a condition that affects approximately 90% of U.S. adults over 45.
Viatris (NASDAQ: VTRS) announced positive Phase 3 study results for its investigational XULANE LO™ low dose contraceptive patch. The study, involving 1,272 women across 81 sites in the U.S., Puerto Rico, and Canada, demonstrated favorable efficacy with a Pearl Index of 4.14 and a 3.7% cumulative pregnancy probability over 13 cycles.
The patch showed strong performance metrics, including excellent adhesion with only 1.3% of patches completely detaching during the seven-day wearing period and less than 1% of subjects reporting severe local application site reactions. Most treatment emergent adverse events were mild-to-moderate, with favorable cycle control and low unscheduled bleeding events. Viatris plans to submit a New Drug Application to the FDA in the second half of 2025.
Viatris (NASDAQ: VTRS) has announced a quarterly dividend payment of $0.12 per share for its common stock shareholders. The dividend was declared by the company's Board of Directors on May 5, 2025. Shareholders who own VTRS stock as of the close of business on May 23, 2025 (record date) will receive the dividend payment on June 16, 2025.
Viatris (NASDAQ: VTRS) has announced significant changes to its Board of Directors. Frank D'Amelio, former Pfizer CFO, and Dr. Michael Severino, current CEO of Tessera Therapeutics, have been appointed as new board members. Meanwhile, current directors Rajiv Malik and Harry Korman will retire at the end of their terms in December 2025.
D'Amelio brings 20 years of experience as a public company CFO, including 15 years at Pfizer where he managed corporate finance functions and global supply. Severino's background includes serving as Vice Chairman and President of AbbVie, where he also held roles as EVP of R&D and Chief Scientific Officer. He previously spent 10 years at Amgen in various leadership positions.
The appointments are part of Viatris' ongoing Board refreshment efforts aimed at accelerating shareholder return and positioning the company for long-term growth.
Viatris (Nasdaq: VTRS), a global healthcare company, has announced its participation in the BofA Securities 2025 Healthcare Conference in Las Vegas. The presentation is scheduled for Tuesday, May 13, 2025, at 5 p.m. PT / 8 p.m. ET.
Investors and interested parties can access a live webcast of the presentation through investor.viatris.com. An archived version will also be available for -time viewing at the same location following the live event.